高通量药物筛选鉴定SMAC模拟物可增强慢性髓性白血病中NK细胞的细胞毒性
研究采用包含500余种小分子化合物的高通量药物筛选,系统评估肿瘤药物对原代NK细胞杀伤慢性髓性白血病(CML)细胞的影响。SMAC模拟物在细胞系和原代患者样本中均增强NK细胞细胞毒性,而糖皮质激素和达沙替尼等酪氨酸激酶抑制剂则抑制NK细胞细胞毒性。单细胞RNA测序显示SMAC模拟物上调NK细胞NF-κB靶基因,抑制性药物阻止NK细胞活化并抑制IFN-γ表达。
要点
- SMAC模拟物在细胞系和原代患者样本中增强NK细胞对CML细胞的细胞毒性。
- 糖皮质激素和达沙替尼等酪氨酸激酶抑制剂抑制NK细胞细胞毒性。
- SMAC模拟物上调NK细胞NF-κB靶基因,可能贡献于增强的细胞毒性。
核心结论
- SMAC模拟物使癌细胞对NK细胞介导的杀伤敏感,尤其在晚期CML患者中具有潜在临床应用价值。
研究设计与样本
- 采用包含500余种小分子化合物的高通量药物筛选,系统评估肿瘤药物对原代NK细胞杀伤CML细胞的影响。
主要发现
- SMAC模拟物在细胞系和原代患者样本中均增强NK细胞细胞毒性。
- 糖皮质激素和达沙替尼等酪氨酸激酶抑制剂抑制NK细胞细胞毒性。
- 单细胞RNA测序显示SMAC模拟物上调NK细胞NF-κB靶基因。
- 地塞米松、达沙替尼和索曲妥林阻止NK细胞向活化状态转变并抑制IFN-γ表达。
临床怎么用
- 原文结论指出SMAC模拟物使癌细胞对NK细胞介导的杀伤敏感,尤其在晚期CML患者中具有潜在临床应用价值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Natural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting NK-cell function with oncological drugs could improve NK-cell-based immunotherapies. Here, we used a high-throughput drug screen consisting of >500 small-molecule compounds, to systematically evaluate the effects of oncological drugs on primary NK cells against CML cells. We identified second mitochondrially derived activator of caspases (SMAC) mimetics as potent enhancers of NK-cell cytotoxicity in both cell lines and primary patient samples. In contrast, several drug classes, including glucocorticoids and tyrosine kinase inhibitors such as dasatinib, inhibited NK-cell cytotoxicity. Single-cell RNA sequencing revealed drug-induced transcriptomic changes in both NK and target CML cells. SMAC mimetics upregulated NF-κB target genes in NK cells, potentially contributing to their enhanced cytotoxicity. Inhibitory drugs dexamethasone, dasatinib, and sotrastaurin prevented NK-cell transition to an activated state and suppressed the expression of interferon gamma (IFN-γ) by NK cells, thus preventing IFN-γ-mediated target cell transcriptomic response. In conclusion, we discovered that SMAC mimetics sensitize cancer cells to NK-cell-mediated killing, with potential clinical applications especially in patients with advanced phase CML.
引用
- Nygrén P, Bouhlal J, Jokinen E, et al. High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia. Blood. 2025. PMID: 39792962. doi:10.1182/blood.2024025286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。